My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 265

    1.

    The protein C pathway: implications for the design of the RESPOND study.

    Vangerow B, Shorr AF, Wyncoll D, Janes J, Nelson DR, Reinhart K.

    Crit Care. 2007;11 Suppl 5:S4. Review.PMID: 18269691 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).

    Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, Janes J.

    Crit Care. 2008;12(2):R45. Epub 2008 Apr 4. Review.PMID: 18394162 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

    Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ; Extended Evaluation of Recombinant Human Activated Protein C United States Investigators.

    Chest. 2004 Jun;125(6):2206-16.PMID: 15189943 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.

    Laterre PF, Macias WL, Janes J, Williams MD, Nelson DR, Girbes AR, Dhainaut JF, Abraham E.

    Crit Care. 2008;12(5):R117. Epub 2008 Sep 11.PMID: 18786266 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

    Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2004 Nov;32(11):2199-206.PMID: 15640631 [PubMed - indexed for MEDLINE]Related articles

    6.

    Clinical trials in severe sepsis with drotrecogin alfa (activated).

    Laterre PF.

    Crit Care. 2007;11 Suppl 5:S5. Review.PMID: 18269692 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

    Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

    N Engl J Med. 2005 Sep 29;353(13):1332-41.PMID: 16192478 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

    Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61. PMID: 17084715 [PubMed - indexed for MEDLINE]Related articles

    9.

    Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.

    Camporota L, Corno E, Menaldo E, Smith J, Lei K, Beale R, Wyncoll D.

    Crit Care. 2008;12(6):R163. Epub 2008 Dec 18.PMID: 19094233 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).

    Short MA, Schlichting D, Qualy RL.

    Curr Med Res Opin. 2006 Dec;22(12):2525-40. Review.PMID: 17265595 [PubMed - indexed for MEDLINE]Related articles

    11.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV.

    Surgery. 2007 Apr;141(4):548-61.PMID: 17431957 [PubMed - indexed for MEDLINE]Related articles

    12.

    International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.

    Sashegyi A, Trzaskoma BL, Nelson DR, Williams MD, Macias W.

    Curr Med Res Opin. 2006 May;22(5):1001-12.PMID: 16709322 [PubMed - indexed for MEDLINE]Related articles

    13.

    Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.

    Barie PS, Hydo LJ, Shou J, Eachempati SR.

    Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.PMID: 16895513 [PubMed - indexed for MEDLINE]Related articles

    14.

    Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.

    Vincent JL, O'Brien J Jr, Wheeler A, Wittebole X, Garg R, Trzaskoma BL, Sundin DP.

    Crit Care. 2006;10(3):R74. Epub 2006 May 9.PMID: 16684364 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.

    Macias WL, Dhainaut JF, Yan SC, Helterbrand JD, Seger M, Johnson G 3rd, Small DS.

    Clin Pharmacol Ther. 2002 Oct;72(4):391-402.PMID: 12386641 [PubMed - indexed for MEDLINE]Related articles

    16.

    A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

    Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

    Crit Care Med. 2008 Jan;36(1):14-23.PMID: 18158435 [PubMed - indexed for MEDLINE]Related articles

    17.

    Drotrecogin alfa (activated): real-life use and outcomes for the UK.

    Rowan KM, Welch CA, North E, Harrison DA.

    Crit Care. 2008;12(2):R58. Epub 2008 Apr 22.PMID: 18430215 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).

    Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL; Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group.

    Am J Respir Crit Care Med. 2007 Sep 1;176(5):483-90. Epub 2007 Jun 7.PMID: 17556722 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.

    Hodder RV, Hall R, Russell JA, Fisher HN, Lee B.

    Crit Care. 2009;13(3):R78. Epub 2009 May 20.PMID: 19457240 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.

    Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC.

    Crit Care Med. 2004 Nov;32(11):2207-18.PMID: 15640632 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk